Lu Xie

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Lu Xie, Jie Xu, Xin Sun et al. · Journal for ImmunoTherapy of Cancer · 2020 · 143 citations · Full text

Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial

Lu Xie, Jie Xu, Xin Sun et al. · The Oncologist · 2018 · 124 citations · Full text

Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

Lu Xie, Wei Guo, Ye Wang et al. · BMC Cancer · 2018 · 63 citations · Full text

Reconstruction of the hemipelvis with a modular prosthesis after resection of a primary malignant peri-acetabular tumour involving the sacroiliac joint

Jie Zang, Wei Guo, Yi Yang et al. · The Bone & Joint Journal · 2014 · 54 citations

Pathologic fracture does not influence local recurrence and survival in high‐grade extremity osteosarcoma with adequate surgical margins

Lu Xie, Wei Guo, Yuanbo Li et al. · Journal of Surgical Oncology · 2012 · 43 citations